Key result
Paquinimod reduces RSV disease severity in infection models by inhibiting IL-17 pathways.
Why the study?
Individual infection models have gaps, which overlapping complementary systems could fill to better understand host immune responses in RSV disease.
Does paquinimod or IL-17 neutralization reduce disease severity and viral load in RSV-infected mice?
Does paquinimod or IL-17 neutralization reduce disease severity and viral load in RSV-infected mice?
Cross-species transcriptomics identified the IL-17/S100A9 pathway as a key driver of RSV pathogenesis, and inhibiting S100A9 with paquinimod reduced disease severity in mice.
Respiratory syncytial virus (RSV) remains a health threat to young children worldwide. The host immune response plays a key role in disease following infection. Infection models advance our understanding of respiratory viruses, but individual models have gaps, which overlapping complementary systems can fill. We compared disease signatures in mice, adults and children; combining transcriptomic data collected from blood, nasal mucosa and lung biopsy following RSV infection. We identified both shared and species-specific pathways triggered by RSV. While systemic responses in children's blood were more similar to those in RSV-challenged adults, mucosal responses during primary infection in mice more closely resembled those in children. We identified an association between IL-17 pathways and RSV pathogenesis and with over-expression of the downstream effectors S100A8 and S100A9. Inhibiting these with the anti-inflammatory drug Paquinimod reduced disease. Here we demonstrate that integrating mouse and human transcriptomic data can identify novel targets to treat RSV disease.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2026) studied Respiratory syncytial virus (RSV) infection. RSV infection was evaluated on Transcriptomic disease signatures and pathways. Cross-species transcriptomic analysis identified an association between IL-17 pathways and RSV pathogenesis, and inhibiting downstream effectors with Paquinimod reduced disease.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: